Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program.

Abstract

BACKGROUND The DNA methylating agent temozolomide was developed primarily for treatment of glioblastoma. However, preclinical data have suggested a broader application for treatment of childhood cancer. Temozolomide was tested against the PPTP solid tumor and ALL models. PROCEDURES Temozolomide was tested against the PPTP in vitro panel at concentrations… (More)
DOI: 10.1002/pbc.24368

Topics

  • Presentations referencing similar topics